Bicara Therapeutics Inc

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Founded in 2018 or 2020, the company is headquartered in Boston, Massachusetts, United States. Bicara Therapeutics is a publicly held company trading on Nasdaq under the ticker symbol BCAX. As of May 2026, its market capitalization is approximately $1.34 billion to $1.42 billion, with around 103 employees as of December 2025.

Bicara's primary product line revolves around its lead program, ficerafusp alfa (BCA101), a first-in-class, dual-action, bifunctional antibody. This therapy is designed to target both the epidermal growth factor receptor (EGFR) and transforming growth factor-beta (TGF-β) to improve outcomes for patients with solid tumors. Ficerafusp alfa is currently in clinical development for various solid tumor types, with a significant focus on recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The company's strategy emphasizes combining targeted therapy with immune modulation.

Bicara Therapeutics Inc. has been involved in patent litigation as a plaintiff in a single tracked case. The company initiated a post-grant review (PGR) against Johns Hopkins University at the United States Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) on February 10, 2026. The case, Bicara Therapeutics Inc v. Johns Hopkins University, challenges the patentability of U.S. Patent No. 12,295,968, which broadly discloses genera of targeting moieties and fusion proteins, including fusion antibodies.

In late 2024, Bicara Therapeutics and its former parent company, Biocon, faced accusations of intellectual property theft in a lawsuit filed by Y-Trap, Inc. Y-Trap alleged that Biocon purloined confidential information to file patents around a novel immunotherapy approach and subsequently launched Bicara to develop and commercialize the technology. Bicara has stated that it is aware of Y-Trap's complaints and believes the claims are "without merit." Separately, Johns Hopkins University has been involved in other PTAB proceedings with Merck Sharp & Dohme LLC concerning pembrolizumab patents, some of which were found unpatentable.